Global Lucentis (Ranibizumab) and Biosimilar Supply, Demand and Key Producers, 2023-2029
The global Lucentis (Ranibizumab) and Biosimilar market size is expected to reach $ 971.5 million by 2029, rising at a market growth of -2.5% CAGR during the forecast period (2023-2029).
Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.
This report studies the global Lucentis (Ranibizumab) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Lucentis (Ranibizumab) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Lucentis (Ranibizumab) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Lucentis (Ranibizumab) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Lucentis (Ranibizumab) and Biosimilar total production value, 2018-2029, (USD Million)
Global Lucentis (Ranibizumab) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Lucentis (Ranibizumab) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Lucentis (Ranibizumab) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Lucentis (Ranibizumab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Coherus and Biogen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Lucentis (Ranibizumab) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Lucentis (Ranibizumab) and Biosimilar Market, By Region:
1. How big is the global Lucentis (Ranibizumab) and Biosimilar market?
2. What is the demand of the global Lucentis (Ranibizumab) and Biosimilar market?
3. What is the year over year growth of the global Lucentis (Ranibizumab) and Biosimilar market?
4. What is the production and production value of the global Lucentis (Ranibizumab) and Biosimilar market?
5. Who are the key producers in the global Lucentis (Ranibizumab) and Biosimilar market?
6. What are the growth factors driving the market demand?
Ranibizumab is a medication used to manage and treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, myopic choroidal neovascularization, and diabetic retinopathy.
This report studies the global Lucentis (Ranibizumab) and Biosimilar production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Lucentis (Ranibizumab) and Biosimilar, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Lucentis (Ranibizumab) and Biosimilar that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Lucentis (Ranibizumab) and Biosimilar total production and demand, 2018-2029, (K Units)
Global Lucentis (Ranibizumab) and Biosimilar total production value, 2018-2029, (USD Million)
Global Lucentis (Ranibizumab) and Biosimilar production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar consumption by region & country, CAGR, 2018-2029 & (K Units)
U.S. VS China: Lucentis (Ranibizumab) and Biosimilar domestic production, consumption, key domestic manufacturers and share
Global Lucentis (Ranibizumab) and Biosimilar production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)
Global Lucentis (Ranibizumab) and Biosimilar production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units)
This reports profiles key players in the global Lucentis (Ranibizumab) and Biosimilar market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Coherus and Biogen, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Lucentis (Ranibizumab) and Biosimilar market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Lucentis (Ranibizumab) and Biosimilar Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Brand
- Biosimilar
- Hospital
- Pharmacy
- Other
- Roche
- Coherus
- Biogen
1. How big is the global Lucentis (Ranibizumab) and Biosimilar market?
2. What is the demand of the global Lucentis (Ranibizumab) and Biosimilar market?
3. What is the year over year growth of the global Lucentis (Ranibizumab) and Biosimilar market?
4. What is the production and production value of the global Lucentis (Ranibizumab) and Biosimilar market?
5. Who are the key producers in the global Lucentis (Ranibizumab) and Biosimilar market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Lucentis (Ranibizumab) and Biosimilar Introduction
1.2 World Lucentis (Ranibizumab) and Biosimilar Supply & Forecast
1.2.1 World Lucentis (Ranibizumab) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.2.3 World Lucentis (Ranibizumab) and Biosimilar Pricing Trends (2018-2029)
1.3 World Lucentis (Ranibizumab) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Lucentis (Ranibizumab) and Biosimilar Production by Region (2018-2029)
1.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.5 Europe Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.6 China Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.7 Japan Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Lucentis (Ranibizumab) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Lucentis (Ranibizumab) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Lucentis (Ranibizumab) and Biosimilar Demand (2018-2029)
2.2 World Lucentis (Ranibizumab) and Biosimilar Consumption by Region
2.2.1 World Lucentis (Ranibizumab) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Lucentis (Ranibizumab) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.4 China Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.5 Europe Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.6 Japan Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.7 South Korea Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.9 India Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
3 WORLD LUCENTIS (RANIBIZUMAB) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Lucentis (Ranibizumab) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Lucentis (Ranibizumab) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Lucentis (Ranibizumab) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Lucentis (Ranibizumab) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Lucentis (Ranibizumab) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Lucentis (Ranibizumab) and Biosimilar in 2022
3.6 Lucentis (Ranibizumab) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Lucentis (Ranibizumab) and Biosimilar Market: Region Footprint
3.6.2 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint
3.6.3 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Comparison
4.2.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
4.5 China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Lucentis (Ranibizumab) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Lucentis (Ranibizumab) and Biosimilar Production by Type (2018-2029)
5.3.2 World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Lucentis (Ranibizumab) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Lucentis (Ranibizumab) and Biosimilar Production by Application (2018-2029)
6.3.2 World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Lucentis (Ranibizumab) and Biosimilar Product and Services
7.1.4 Roche Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Coherus
7.2.1 Coherus Details
7.2.2 Coherus Major Business
7.2.3 Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services
7.2.4 Coherus Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Coherus Recent Developments/Updates
7.2.6 Coherus Competitive Strengths & Weaknesses
7.3 Biogen
7.3.1 Biogen Details
7.3.2 Biogen Major Business
7.3.3 Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services
7.3.4 Biogen Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Biogen Recent Developments/Updates
7.3.6 Biogen Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Lucentis (Ranibizumab) and Biosimilar Industry Chain
8.2 Lucentis (Ranibizumab) and Biosimilar Upstream Analysis
8.2.1 Lucentis (Ranibizumab) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Lucentis (Ranibizumab) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Lucentis (Ranibizumab) and Biosimilar Production Mode
8.6 Lucentis (Ranibizumab) and Biosimilar Procurement Model
8.7 Lucentis (Ranibizumab) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Lucentis (Ranibizumab) and Biosimilar Sales Model
8.7.2 Lucentis (Ranibizumab) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Lucentis (Ranibizumab) and Biosimilar Introduction
1.2 World Lucentis (Ranibizumab) and Biosimilar Supply & Forecast
1.2.1 World Lucentis (Ranibizumab) and Biosimilar Production Value (2018 & 2022 & 2029)
1.2.2 World Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.2.3 World Lucentis (Ranibizumab) and Biosimilar Pricing Trends (2018-2029)
1.3 World Lucentis (Ranibizumab) and Biosimilar Production by Region (Based on Production Site)
1.3.1 World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018-2029)
1.3.2 World Lucentis (Ranibizumab) and Biosimilar Production by Region (2018-2029)
1.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2029)
1.3.4 North America Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.5 Europe Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.6 China Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.3.7 Japan Lucentis (Ranibizumab) and Biosimilar Production (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Lucentis (Ranibizumab) and Biosimilar Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Lucentis (Ranibizumab) and Biosimilar Major Market Trends
1.5 Influence of COVID-19 and Russia-Ukraine War
1.5.1 Influence of COVID-19
1.5.2 Influence of Russia-Ukraine War
2 DEMAND SUMMARY
2.1 World Lucentis (Ranibizumab) and Biosimilar Demand (2018-2029)
2.2 World Lucentis (Ranibizumab) and Biosimilar Consumption by Region
2.2.1 World Lucentis (Ranibizumab) and Biosimilar Consumption by Region (2018-2023)
2.2.2 World Lucentis (Ranibizumab) and Biosimilar Consumption Forecast by Region (2024-2029)
2.3 United States Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.4 China Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.5 Europe Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.6 Japan Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.7 South Korea Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.8 ASEAN Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
2.9 India Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029)
3 WORLD LUCENTIS (RANIBIZUMAB) AND BIOSIMILAR MANUFACTURERS COMPETITIVE ANALYSIS
3.1 World Lucentis (Ranibizumab) and Biosimilar Production Value by Manufacturer (2018-2023)
3.2 World Lucentis (Ranibizumab) and Biosimilar Production by Manufacturer (2018-2023)
3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023)
3.4 Lucentis (Ranibizumab) and Biosimilar Company Evaluation Quadrant
3.5 Industry Rank and Concentration Rate (CR)
3.5.1 Global Lucentis (Ranibizumab) and Biosimilar Industry Rank of Major Manufacturers
3.5.2 Global Concentration Ratios (CR4) for Lucentis (Ranibizumab) and Biosimilar in 2022
3.5.3 Global Concentration Ratios (CR8) for Lucentis (Ranibizumab) and Biosimilar in 2022
3.6 Lucentis (Ranibizumab) and Biosimilar Market: Overall Company Footprint Analysis
3.6.1 Lucentis (Ranibizumab) and Biosimilar Market: Region Footprint
3.6.2 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint
3.6.3 Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application Footprint
3.7 Competitive Environment
3.7.1 Historical Structure of the Industry
3.7.2 Barriers of Market Entry
3.7.3 Factors of Competition
3.8 New Entrant and Capacity Expansion Plans
3.9 Mergers, Acquisition, Agreements, and Collaborations
4 UNITED STATES VS CHINA VS REST OF THE WORLD
4.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Comparison
4.1.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Comparison (2018 & 2022 & 2029)
4.1.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
4.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Comparison
4.2.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
4.3 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Comparison
4.3.1 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Comparison (2018 & 2022 & 2029)
4.3.2 United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
4.4 United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.4.1 United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
4.4.2 United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.4.3 United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
4.5 China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share
4.5.1 China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
4.5.2 China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.5.3 China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
4.6 Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers and Market Share, 2018-2023
4.6.1 Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (State, Country)
4.6.2 Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value (2018-2023)
4.6.3 Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Lucentis (Ranibizumab) and Biosimilar Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Brand
5.2.2 Biosimilar
5.3 Market Segment by Type
5.3.1 World Lucentis (Ranibizumab) and Biosimilar Production by Type (2018-2029)
5.3.2 World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2018-2029)
5.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Lucentis (Ranibizumab) and Biosimilar Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Lucentis (Ranibizumab) and Biosimilar Production by Application (2018-2029)
6.3.2 World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2018-2029)
6.3.3 World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029)
7 COMPANY PROFILES
7.1 Roche
7.1.1 Roche Details
7.1.2 Roche Major Business
7.1.3 Roche Lucentis (Ranibizumab) and Biosimilar Product and Services
7.1.4 Roche Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.1.5 Roche Recent Developments/Updates
7.1.6 Roche Competitive Strengths & Weaknesses
7.2 Coherus
7.2.1 Coherus Details
7.2.2 Coherus Major Business
7.2.3 Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services
7.2.4 Coherus Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.2.5 Coherus Recent Developments/Updates
7.2.6 Coherus Competitive Strengths & Weaknesses
7.3 Biogen
7.3.1 Biogen Details
7.3.2 Biogen Major Business
7.3.3 Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services
7.3.4 Biogen Lucentis (Ranibizumab) and Biosimilar Production, Price, Value, Gross Margin and Market Share (2018-2023)
7.3.5 Biogen Recent Developments/Updates
7.3.6 Biogen Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Lucentis (Ranibizumab) and Biosimilar Industry Chain
8.2 Lucentis (Ranibizumab) and Biosimilar Upstream Analysis
8.2.1 Lucentis (Ranibizumab) and Biosimilar Core Raw Materials
8.2.2 Main Manufacturers of Lucentis (Ranibizumab) and Biosimilar Core Raw Materials
8.3 Midstream Analysis
8.4 Downstream Analysis
8.5 Lucentis (Ranibizumab) and Biosimilar Production Mode
8.6 Lucentis (Ranibizumab) and Biosimilar Procurement Model
8.7 Lucentis (Ranibizumab) and Biosimilar Industry Sales Model and Sales Channels
8.7.1 Lucentis (Ranibizumab) and Biosimilar Sales Model
8.7.2 Lucentis (Ranibizumab) and Biosimilar Typical Customers
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Lucentis (Ranibizumab) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Lucentis (Ranibizumab) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Lucentis (Ranibizumab) and Biosimilar Major Market Trends
Table 13. World Lucentis (Ranibizumab) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Lucentis (Ranibizumab) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Lucentis (Ranibizumab) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Lucentis (Ranibizumab) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Lucentis (Ranibizumab) and Biosimilar Producers in 2022
Table 18. World Lucentis (Ranibizumab) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Lucentis (Ranibizumab) and Biosimilar Producers in 2022
Table 20. World Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Lucentis (Ranibizumab) and Biosimilar Company Evaluation Quadrant
Table 22. World Lucentis (Ranibizumab) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Lucentis (Ranibizumab) and Biosimilar Production Site of Key Manufacturer
Table 24. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint
Table 25. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application Footprint
Table 26. Lucentis (Ranibizumab) and Biosimilar Competitive Factors
Table 27. Lucentis (Ranibizumab) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Lucentis (Ranibizumab) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Lucentis (Ranibizumab) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Lucentis (Ranibizumab) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Lucentis (Ranibizumab) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 47. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Lucentis (Ranibizumab) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Lucentis (Ranibizumab) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Lucentis (Ranibizumab) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Lucentis (Ranibizumab) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 64. Roche Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Coherus Basic Information, Manufacturing Base and Competitors
Table 68. Coherus Major Business
Table 69. Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 70. Coherus Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Coherus Recent Developments/Updates
Table 72. Biogen Basic Information, Manufacturing Base and Competitors
Table 73. Biogen Major Business
Table 74. Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 75. Biogen Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 76. Global Key Players of Lucentis (Ranibizumab) and Biosimilar Upstream (Raw Materials)
Table 77. Lucentis (Ranibizumab) and Biosimilar Typical Customers
Table 78. Lucentis (Ranibizumab) and Biosimilar Typical Distributors
Table 1. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018, 2022 and 2029) & (USD Million)
Table 2. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2018-2023) & (USD Million)
Table 3. World Lucentis (Ranibizumab) and Biosimilar Production Value by Region (2024-2029) & (USD Million)
Table 4. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2018-2023)
Table 5. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2024-2029)
Table 6. World Lucentis (Ranibizumab) and Biosimilar Production by Region (2018-2023) & (K Units)
Table 7. World Lucentis (Ranibizumab) and Biosimilar Production by Region (2024-2029) & (K Units)
Table 8. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2018-2023)
Table 9. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2024-2029)
Table 10. World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2018-2023) & (US$/Unit)
Table 11. World Lucentis (Ranibizumab) and Biosimilar Average Price by Region (2024-2029) & (US$/Unit)
Table 12. Lucentis (Ranibizumab) and Biosimilar Major Market Trends
Table 13. World Lucentis (Ranibizumab) and Biosimilar Consumption Growth Rate Forecast by Region (2018 & 2022 & 2029) & (K Units)
Table 14. World Lucentis (Ranibizumab) and Biosimilar Consumption by Region (2018-2023) & (K Units)
Table 15. World Lucentis (Ranibizumab) and Biosimilar Consumption Forecast by Region (2024-2029) & (K Units)
Table 16. World Lucentis (Ranibizumab) and Biosimilar Production Value by Manufacturer (2018-2023) & (USD Million)
Table 17. Production Value Market Share of Key Lucentis (Ranibizumab) and Biosimilar Producers in 2022
Table 18. World Lucentis (Ranibizumab) and Biosimilar Production by Manufacturer (2018-2023) & (K Units)
Table 19. Production Market Share of Key Lucentis (Ranibizumab) and Biosimilar Producers in 2022
Table 20. World Lucentis (Ranibizumab) and Biosimilar Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Global Lucentis (Ranibizumab) and Biosimilar Company Evaluation Quadrant
Table 22. World Lucentis (Ranibizumab) and Biosimilar Industry Rank of Major Manufacturers, Based on Production Value in 2022
Table 23. Head Office and Lucentis (Ranibizumab) and Biosimilar Production Site of Key Manufacturer
Table 24. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Type Footprint
Table 25. Lucentis (Ranibizumab) and Biosimilar Market: Company Product Application Footprint
Table 26. Lucentis (Ranibizumab) and Biosimilar Competitive Factors
Table 27. Lucentis (Ranibizumab) and Biosimilar New Entrant and Capacity Expansion Plans
Table 28. Lucentis (Ranibizumab) and Biosimilar Mergers & Acquisitions Activity
Table 29. United States VS China Lucentis (Ranibizumab) and Biosimilar Production Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 30. United States VS China Lucentis (Ranibizumab) and Biosimilar Production Comparison, (2018 & 2022 & 2029) & (K Units)
Table 31. United States VS China Lucentis (Ranibizumab) and Biosimilar Consumption Comparison, (2018 & 2022 & 2029) & (K Units)
Table 32. United States Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 33. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 34. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 35. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 36. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 37. China Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (Province, Country)
Table 38. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 39. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 40. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 41. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 42. Rest of World Based Lucentis (Ranibizumab) and Biosimilar Manufacturers, Headquarters and Production Site (States, Country)
Table 43. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value, (2018-2023) & (USD Million)
Table 44. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Value Market Share (2018-2023)
Table 45. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production (2018-2023) & (K Units)
Table 46. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share (2018-2023)
Table 47. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Table 48. World Lucentis (Ranibizumab) and Biosimilar Production by Type (2018-2023) & (K Units)
Table 49. World Lucentis (Ranibizumab) and Biosimilar Production by Type (2024-2029) & (K Units)
Table 50. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2018-2023) & (USD Million)
Table 51. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type (2024-2029) & (USD Million)
Table 52. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2023) & (US$/Unit)
Table 53. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2024-2029) & (US$/Unit)
Table 54. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Table 55. World Lucentis (Ranibizumab) and Biosimilar Production by Application (2018-2023) & (K Units)
Table 56. World Lucentis (Ranibizumab) and Biosimilar Production by Application (2024-2029) & (K Units)
Table 57. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2018-2023) & (USD Million)
Table 58. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application (2024-2029) & (USD Million)
Table 59. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2023) & (US$/Unit)
Table 60. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2024-2029) & (US$/Unit)
Table 61. Roche Basic Information, Manufacturing Base and Competitors
Table 62. Roche Major Business
Table 63. Roche Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 64. Roche Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 65. Roche Recent Developments/Updates
Table 66. Roche Competitive Strengths & Weaknesses
Table 67. Coherus Basic Information, Manufacturing Base and Competitors
Table 68. Coherus Major Business
Table 69. Coherus Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 70. Coherus Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 71. Coherus Recent Developments/Updates
Table 72. Biogen Basic Information, Manufacturing Base and Competitors
Table 73. Biogen Major Business
Table 74. Biogen Lucentis (Ranibizumab) and Biosimilar Product and Services
Table 75. Biogen Lucentis (Ranibizumab) and Biosimilar Production (K Units), Price (US$/Unit), Production Value (USD Million), Gross Margin and Market Share (2018-2023)
Table 76. Global Key Players of Lucentis (Ranibizumab) and Biosimilar Upstream (Raw Materials)
Table 77. Lucentis (Ranibizumab) and Biosimilar Typical Customers
Table 78. Lucentis (Ranibizumab) and Biosimilar Typical Distributors
LIST OF FIGURES
Figure 1. Lucentis (Ranibizumab) and Biosimilar Picture
Figure 2. World Lucentis (Ranibizumab) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Lucentis (Ranibizumab) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Lucentis (Ranibizumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Lucentis (Ranibizumab) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Lucentis (Ranibizumab) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Lucentis (Ranibizumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Lucentis (Ranibizumab) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Lucentis (Ranibizumab) and Biosimilar Markets in 2022
Figure 26. United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 32. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Pharmacy
Figure 43. Other
Figure 44. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Application (2018-2029)
Figure 45. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 46. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Lucentis (Ranibizumab) and Biosimilar Industry Chain
Figure 48. Lucentis (Ranibizumab) and Biosimilar Procurement Model
Figure 49. Lucentis (Ranibizumab) and Biosimilar Sales Model
Figure 50. Lucentis (Ranibizumab) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
Figure 1. Lucentis (Ranibizumab) and Biosimilar Picture
Figure 2. World Lucentis (Ranibizumab) and Biosimilar Production Value: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Lucentis (Ranibizumab) and Biosimilar Production Value and Forecast (2018-2029) & (USD Million)
Figure 4. World Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 5. World Lucentis (Ranibizumab) and Biosimilar Average Price (2018-2029) & (US$/Unit)
Figure 6. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Region (2018-2029)
Figure 7. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Region (2018-2029)
Figure 8. North America Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 9. Europe Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 10. China Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 11. Japan Lucentis (Ranibizumab) and Biosimilar Production (2018-2029) & (K Units)
Figure 12. Lucentis (Ranibizumab) and Biosimilar Market Drivers
Figure 13. Factors Affecting Demand
Figure 14. World Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 15. World Lucentis (Ranibizumab) and Biosimilar Consumption Market Share by Region (2018-2029)
Figure 16. United States Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 17. China Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 18. Europe Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 19. Japan Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 20. South Korea Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 21. ASEAN Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 22. India Lucentis (Ranibizumab) and Biosimilar Consumption (2018-2029) & (K Units)
Figure 23. Producer Shipments of Lucentis (Ranibizumab) and Biosimilar by Manufacturer Revenue ($MM) and Market Share (%): 2022
Figure 24. Global Four-firm Concentration Ratios (CR4) for Lucentis (Ranibizumab) and Biosimilar Markets in 2022
Figure 25. Global Four-firm Concentration Ratios (CR8) for Lucentis (Ranibizumab) and Biosimilar Markets in 2022
Figure 26. United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Value Market Share Comparison (2018 & 2022 & 2029)
Figure 27. United States VS China: Lucentis (Ranibizumab) and Biosimilar Production Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Lucentis (Ranibizumab) and Biosimilar Consumption Market Share Comparison (2018 & 2022 & 2029)
Figure 29. United States Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 30. China Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 31. Rest of World Based Manufacturers Lucentis (Ranibizumab) and Biosimilar Production Market Share 2022
Figure 32. World Lucentis (Ranibizumab) and Biosimilar Production Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 33. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Type in 2022
Figure 34. Brand
Figure 35. Biosimilar
Figure 36. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Type (2018-2029)
Figure 37. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Type (2018-2029)
Figure 38. World Lucentis (Ranibizumab) and Biosimilar Average Price by Type (2018-2029) & (US$/Unit)
Figure 39. World Lucentis (Ranibizumab) and Biosimilar Production Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 40. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Application in 2022
Figure 41. Hospital
Figure 42. Pharmacy
Figure 43. Other
Figure 44. World Lucentis (Ranibizumab) and Biosimilar Production Market Share by Application (2018-2029)
Figure 45. World Lucentis (Ranibizumab) and Biosimilar Production Value Market Share by Application (2018-2029)
Figure 46. World Lucentis (Ranibizumab) and Biosimilar Average Price by Application (2018-2029) & (US$/Unit)
Figure 47. Lucentis (Ranibizumab) and Biosimilar Industry Chain
Figure 48. Lucentis (Ranibizumab) and Biosimilar Procurement Model
Figure 49. Lucentis (Ranibizumab) and Biosimilar Sales Model
Figure 50. Lucentis (Ranibizumab) and Biosimilar Sales Channels, Direct Sales, and Distribution
Figure 51. Methodology
Figure 52. Research Process and Data Source
